Touting programs from Novartis, Laekna bags $100M in Hong Kong IPO while Merck-partnered Kelun seeks up to $208M
A pair of Chinese biotechs with Big Pharma ties is bringing some fresh IPO activity to the biotech corner of Hong Kong’s stock exchange after …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
